Our management team consists of experienced biopharma executives with complementary backgrounds, including corporate governance, finance, medicine and science.
Ronopterin is the first and only selective inhibitor of inducible Nitric Oxide Synthase (iNOS) which has repeatedly shown signs of biochemical and clinical neuroprotection in patients with traumatic brain injury (TBI).